This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

RBCC: TheraKine Joint Venture Offers Significant Opportunity In Licensing

Only days after signing a joint venture agreement with cutting-edge drug delivery innovators TheraKine, Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC) is working hard to ensure that the partnership will be a fruitful one. Already, the company is searching for new targets that would benefit from adding licenses for the drug delivery protocols TheraKine and RBCC plan to roll out.

The global market for drug delivery technologies is driven by biologics and medications that can’t be administered effectively through traditional means. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015.

In order to capture a piece of that growth, RBCC is seeking out healthcare providers for whom TheraKine’s advanced sustained-release delivery system could yield significant returns for their clients. TheraKine has developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.

“Licensing this incredible new platform is going to be one of the key opportunities to making this a successful partnership,” said RBCC CEO Patrick Brown. “It’s a top priority for our company moving forward. The potential is limitless.”

Rainbow BioSciences develops and markets new medical and research technology innovations to compete in a fast-growing industry alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Valeant Pharmaceuticals International (NYSE: VRX).

RBCC is dedicated to delivering new medical research and technologies to a hungry global marketplace. For more information on RBCC’s initiatives, please visit

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit For investment information and performance data on the Company, please visit

About TheraKine Ltd.

TheraKine Ltd. is a privately held platform technology company with laboratories in Berlin (Germany). TheraKine provides innovative reformulation to enable sustained release for pharmaceutical and biological companies worldwide.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs